Patents by Inventor Carolina Abrutzky

Carolina Abrutzky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dry powder compositions for intranasal delivery
    Patent number: 11844859
    Abstract: Dry powder pharmaceutical compositions for intranasal administration include an opioid receptor antagonist, e.g. naloxone, as active ingredient, and dosage unit forms thereof. Methods of treating opioid overdose include administering the dry powder compositions.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: December 19, 2023
    Assignee: Nasus Pharma Ltd.
    Inventors: Galia Temtsin-Krayz, Dalia Megiddo, Tair Lapidot, Carolina Abrutzky
  • Dry powder compositions for intranasal delivery
    Patent number: 11202757
    Abstract: A pharmaceutical composition in a form of dry powder for intranasal administration includes solid particles of at least one opioid receptor antagonist as active ingredient and two types of solid particles. A naloxone pharmaceutical composition in the form of dry powder for intranasal administration, including as active agent naloxone or a pharmaceutically acceptable salt thereof. A kit for intranasal administration of naloxone. A method of treating opioid overdose/intoxication and/or a symptom thereof in a patient in need thereof by intranasally administering a therapeutically effective amount of a composition including solid particles of at least one opioid receptor antagonist as active ingredient and two types of solid particles.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: December 21, 2021
    Assignee: Formulex Pharma Innovations Ltd.
    Inventors: Galia Temtsin-Krayz, Dalia Megiddo, Tair Lapidot, Carolina Abrutzky
  • Polymeric Compositions for Intranasal Administration
    Publication number: 20210283074
    Abstract: A composition in the form of dry powder for intranasal administration, having solid particles, each having a physiologically acceptable mucoadhesive polymer in combination with at least one functional additive such as pH adjusting agent, with at least about 90% of the particles having a size of about 25-300 microns, and various prophylactic and preventive uses thereof.
    Type: Application
    Filed: December 15, 2020
    Publication date: September 16, 2021
    Inventors: Tair Lapidot, Galia Temtsin-Krayz, Carolina Abrutzky, Dalia Megiddo
  • Dry Powder Compositions for Intranasal Delivery
    Publication number: 20210128462
    Abstract: Dry powder pharmaceutical compositions for intranasal administration include an opioid receptor antagonist, e.g. naloxone, as active ingredient, and dosage unit forms thereof. Methods of treating opioid overdose include administering the dry powder compositions.
    Type: Application
    Filed: November 19, 2020
    Publication date: May 6, 2021
    Inventors: Galia Temtsin-Krayz, Dalia Megiddo, Tair Lapidot, Carolina Abrutzky
  • Dry Powder Compositions for Intranasal Delivery
    Publication number: 20210077390
    Abstract: A pharmaceutical composition in a form of dry powder for intranasal administration includes solid particles of at least one opioid receptor antagonist as active ingredient and two types of solid particles. A naloxone pharmaceutical composition in the form of dry powder for intranasal administration, including as active agent naloxone or a pharmaceutically acceptable salt thereof. A kit for intranasal administration of naloxone.
    Type: Application
    Filed: December 1, 2020
    Publication date: March 18, 2021
    Inventors: Galia Temtsin-Krayz, Dalia Megiddo, Tair Lapidot, Carolina Abrutzky